KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Deffered Revenue (2017 - 2026)

Moderna (MRNA) has disclosed Non-Current Deffered Revenue for 10 consecutive years, with $154.0 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Deffered Revenue rose 165.52% year-over-year to $154.0 million; the TTM value through Mar 2026 reached $154.0 million, up 165.52%, while the annual FY2025 figure was $153.0 million, 163.79% up from the prior year.
  • Non-Current Deffered Revenue hit $154.0 million in Q1 2026 for Moderna, up from $153.0 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $692.0 million in Q2 2023 and bottomed at $58.0 million in Q1 2024.
  • Average Non-Current Deffered Revenue over 5 years is $248.5 million, with a median of $154.0 million recorded in 2026.
  • Year-over-year, Non-Current Deffered Revenue plummeted 91.38% in 2024 and then soared 165.52% in 2026.
  • Moderna's Non-Current Deffered Revenue stood at $673.0 million in 2022, then crashed by 87.67% to $83.0 million in 2023, then crashed by 30.12% to $58.0 million in 2024, then soared by 163.79% to $153.0 million in 2025, then rose by 0.65% to $154.0 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $154.0 million, $153.0 million, and $157.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.